Rising a Novel Weapon in the War against Gout and Hyperuricemia

Jung Soo Song

doi:10.4078/jrd.2016.23.1.1

Journal List > J Rheum Dis > v.23(1) > 1064246

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Song: Rising a Novel Weapon in the War against Gout and Hyperuricemia

Editorial

J Rheum Dis 2016;23(1):1-3.

Published online: 31 October 2016

DOI: https://doi.org/10.4078/jrd.2016.23.1.1

Rising a Novel Weapon in the War against Gout and Hyperuricemia

Jung Soo Song

Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

Corresponding to: Jung Soo Song, Division of Rheumatology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. E-mail: drsong@cau.ac.kr

Received 1 January 2016 Revised 13 January 2016 Accepted 13 January 20116

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

1. Neogi T. Clinical practice. Gout. N Engl J Med. 2011; 364:443–52.

2. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013; 72:694–700.

3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63:3136–41.

4. Bardin T, Bouée S, Clerson P, Chalès G, Flipo RM, Lioté F, et al. Prevalence of gout in the adult population of France. Arthritis Care Res (Hoboken). 2016; 68:261–6.

5. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008; 67:960–6.

6. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015; 74:661–7.

7. Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A, et al. Gout, diabetes and cardiovascular disease in the ao-tearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J. 2012; 126:53–64.

8. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol. 1988; 41:237–42.

9. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54:2688–96.

10. Sheane BJ, Cunnane G. Tophaceous gout and chronic kidney disease. J Clin Rheumatol. 2007; 13:293.

11. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007; 116:894–900.

12. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008; 168:1104–10.

13. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010; 49:141–6.

14. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005; 44:1038–42.

15. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006; 33:104–9.

16. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76:47–56.

17. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993; 27:337–43.

18. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twen-ty-eight-day, multicenter, phase II, randomized, doubleblind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52:916–23.

19. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40:2187–94.

20. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59:1540–8.

21. Song GG, Lee YH. Comparative efficacy and safety of febuxostat and allopurinol in the treatment of hyperuricemia: a Bayesian network meta-analysis. J Rheum Dis. 2015; 22:356–65.

22. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B. Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014; 34:1489–96.

23. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331:897–900.

TOOLS

Similar articles